Parallax Volatility Advisers
LEGN icon

Parallax Volatility Advisers’s Legend Biotech LEGN Stock Holding History

Parallax Volatility Advisers’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,000
Closed -$616K – 3232
2021
Q2 		$616K Buy
+15,000
New +$510K ﹤0.01% 2112

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Parallax Volatility Advisers's LEGN Position: Q1 2023 in Review

Parallax Volatility Advisers sold out of Legend Biotech (LEGN) in Q1 2023, closing a stake of 15,556 shares — an estimated $777K sold.

Parallax Volatility Advisers first reported a position in LEGN in Q3 2022 and held it in 2 quarters. The position peaked at $797K in Q3 2022. 160 funds tracked by Wall St. Rank hold LEGN as of Q1 2023.

  • Parallax Volatility Advisers reported no remaining Legend Biotech position as of Q1 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 15,556 Legend Biotech shares in Q1 2023, an estimated $777K.
  • Parallax Volatility Advisers first reported a position in Legend Biotech in Q3 2022 and held it in 2 quarters.
  • Parallax Volatility Advisers's Legend Biotech position peaked at $797K in Q3 2022.
  • 160 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2023.

Based on Parallax Volatility Advisers's 13F filing for Q1 2023, filed 15 May 2023.